Cancer is no longer just a disease of old age. With changing lifestyles, genetics, and
environmental factors influencing health, more women are being diagnosed with cancer at
younger ages. The encouraging news is that many cancers are highly treatable and in some
cases preventable when detected early. Here are the key facts every woman should know
about preventive cancer screening.
- Early Detection Can Significantly Improve Survival
Detecting cancer before symptoms appear often leads to more treatment options, less aggressive therapies, and better outcomes. Studies show that survival rates improve dramatically when cancers are diagnosed in their earliest stages. In India, however, most cancers continue to be detected late, contributing to poorer outcomes. Recent estimates indicate that only about 29% of cancers in India are diagnosed at an early stage, with just 15% of breast and lung cancers and 33% of cervical cancers identified at stages I–II, underscoring a significant gap in timely diagnosis. Additionally, India’s cancer burden continues to rise, with an estimated 1.56 million new cancer cases in 2024, projected to increase to 2.83 million by 2050, highlighting the urgent need for improved screening and early detection strategies
- Screening Isn’t Only for Women With Symptoms
Many cancers develop silently and may not show noticeable symptoms until they have progressed. Preventive screening is designed to identify risks or detect cancer early even when you feel completely healthy. For individuals at average risk, evidence-based guidelines recommend initiating screening at specific ages, including cervical cancer screening from age 30, breast cancer screening from age 40, and colorectal cancer screening from age 45. Individuals with a strong family history of cancer, known hereditary cancer syndromes (such as BRCA1/2 or Lynch syndrome), or other high-risk factors may require screening at an earlier age or at more frequent intervals.
- Blood-Based Screening Technologies Are Changing the Landscape
Advances in genomics and liquid biopsy are making cancer screening less invasive and more accessible. Blood-based tests have the potential to detect biological signals associated with cancer at an early stage, supporting timely clinical intervention. CancerSpot is a blood-based multi-cancer early detection (MCED) test developed by Strand Life Sciences that uses targeted cell-free DNA (cfDNA) methylation sequencing and machine learning to detect cancer-associated signals from a single blood sample. In validation studies involving 10 cancer types, CancerSpot achieved 79% sensitivity for Stage I–III cancers, 97% specificity, and 77% accuracy in predicting the tissue of origin within the top two predictions, demonstrating its potential to support earlier cancer detection and timely clinical intervention.
The Bottom Line
Preventive cancer screening empowers women to take charge of their health. As scientific
advances continue to improve early detection, timely screening combined with informed
medical guidance can play a vital role in reducing the burden of cancer and improving long-term
health outcomes.
